bullish

Biopharma Week in Review - September 9, 2024

18 Views11 Sep 2024 06:23
Issuer-paid
Last week, PCVX had pneumococcal vaccine data that could seriously challenge PFE’s market leading Prevnar 20. TVTX celebrated full FDA approval of its IgAN drug, just in time for new KDIGO guidelines.
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 8-minute read)
Discussions
(Paid Plans Only)
chart-bar
Logo
Water Tower Research
Research from Water Tower Research
Water Tower Research
Equity Bottom-UpThematic (Sector/Industry)
  • Loading...
x